FTO is also overexpressed in NAFLD patients, which could be a sign of a poor clinical outcome, although univariate Cox regression must be done to formally recognize FTO as an independent prognostic factor for NAFLD patients.83 Importantly, the gene expression profile and expression level of m6A regulators, as well as clinical prognostic information for NAFLD patients, should be acquired to determine the prognostic significance of m6A regulators in NAFLD. This evidence concerns the gene FTO and metabolic dysfunction-associated steatotic liver disease.